Tafasitamab Regimen Improves PFS in Relapsed/Refractory Follicular Lymphoma

(MedPage Today) -- At the recent American Society of Hematology (ASH) annual meeting, late-breaking phase III data demonstrated that adding tafasitamab (Monjuvi) to lenalidomide (Revlimid) and rituximab (Rituxan) significantly improved progression...